Connection

LAWRENCE DONEHOWER to Mice, Knockout

This is a "connection" page, showing publications LAWRENCE DONEHOWER has written about Mice, Knockout.
Connection Strength

0.918
  1. Mouse models in tumor suppression. Oncogene. 1998 Dec 24; 17(25):3385-400.
    View in: PubMed
    Score: 0.090
  2. Absence of Wip1 partially rescues Atm deficiency phenotypes in mice. Oncogene. 2012 Mar 01; 31(9):1155-65.
    View in: PubMed
    Score: 0.054
  3. The oncogenic phosphatase WIP1 negatively regulates nucleotide excision repair. DNA Repair (Amst). 2010 Jul 01; 9(7):813-23.
    View in: PubMed
    Score: 0.050
  4. Wild-type p53-induced phosphatase 1 dephosphorylates histone variant gamma-H2AX and suppresses DNA double strand break repair. J Biol Chem. 2010 Apr 23; 285(17):12935-47.
    View in: PubMed
    Score: 0.049
  5. 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer. 2009 11; 9(11):831-41.
    View in: PubMed
    Score: 0.048
  6. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell. 2007 Oct; 12(4):342-54.
    View in: PubMed
    Score: 0.041
  7. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood. 2007 Feb 15; 109(4):1736-42.
    View in: PubMed
    Score: 0.039
  8. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice. Mol Carcinog. 2006 Aug; 45(8):594-604.
    View in: PubMed
    Score: 0.038
  9. Homeostatic regulation of base excision repair by a p53-induced phosphatase: linking stress response pathways with DNA repair proteins. Cell Cycle. 2004 Nov; 3(11):1363-6.
    View in: PubMed
    Score: 0.034
  10. The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair. Mol Cell. 2004 Aug 27; 15(4):621-34.
    View in: PubMed
    Score: 0.033
  11. Functional analysis of tumor suppressor genes in mice. Methods Mol Biol. 2003; 223:283-314.
    View in: PubMed
    Score: 0.030
  12. Generation and characterization of p53 mutant mice. Methods Mol Biol. 2003; 234:29-49.
    View in: PubMed
    Score: 0.030
  13. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing. Toxicol Pathol. 2001; 29 Suppl:147-54.
    View in: PubMed
    Score: 0.026
  14. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens. Toxicol Pathol. 2001; 29 Suppl:24-9.
    View in: PubMed
    Score: 0.026
  15. Effect of intragastric application of N-methylnitrosourea in p53 knockout mice. Mol Carcinog. 2000 Jun; 28(2):97-101.
    View in: PubMed
    Score: 0.025
  16. Increased tumor cell proliferation in murine tumors with decreasing dosage of wild-type p53. Mol Carcinog. 1999 Mar; 24(3):197-208.
    View in: PubMed
    Score: 0.023
  17. p53 in embryonic development: maintaining a fine balance. Cell Mol Life Sci. 1999 Jan; 55(1):38-47.
    View in: PubMed
    Score: 0.023
  18. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 1998 Aug 17; 17(16):4657-67.
    View in: PubMed
    Score: 0.022
  19. Murine tumor suppressor models. Mutat Res. 1998 May 25; 400(1-2):391-407.
    View in: PubMed
    Score: 0.022
  20. The p53-deficient mouse: a model for basic and applied cancer studies. Semin Cancer Biol. 1996 Oct; 7(5):269-78.
    View in: PubMed
    Score: 0.019
  21. The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model. Prog Clin Biol Res. 1996; 395:1-11.
    View in: PubMed
    Score: 0.018
  22. Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Med. 2015 Jul; 4(7):977-88.
    View in: PubMed
    Score: 0.017
  23. Gene-targeting and the p53 tumor-suppressor gene. Mutat Res. 1994 Jun 01; 307(2):557-72.
    View in: PubMed
    Score: 0.016
  24. REG? deficiency promotes premature aging via the casein kinase 1 pathway. Proc Natl Acad Sci U S A. 2013 Jul 02; 110(27):11005-10.
    View in: PubMed
    Score: 0.015
  25. Early development of histiocytic sarcomas in p53 knockout mice treated with N-bis(2-hydroxypropyl)nitrosamine. Oncol Rep. 2007 Oct; 18(4):755-61.
    View in: PubMed
    Score: 0.010
  26. Organ-dependent susceptibility of p53 knockout mice to 2-amino-3-methylimidazo[4,5-f]quinoline (IQ). Cancer Sci. 2007 Aug; 98(8):1164-73.
    View in: PubMed
    Score: 0.010
  27. Oxidative and nitrative stress caused by subcutaneous implantation of a foreign body accelerates sarcoma development in Trp53+/- mice. Carcinogenesis. 2007 Jan; 28(1):191-8.
    View in: PubMed
    Score: 0.010
  28. Organ-specific susceptibility of p53 knockout mice to N-bis(2-hydroxypropyl)nitrosamine carcinogenesis. Cancer Lett. 2006 Jul 18; 238(2):271-83.
    View in: PubMed
    Score: 0.009
  29. Diet-gene interactions in p53-deficient mice: insulin-like growth factor-1 as a mechanistic target. J Nutr. 2004 Sep; 134(9):2482S-2486S.
    View in: PubMed
    Score: 0.008
  30. Loss of heterozygosity occurs via mitotic recombination in Trp53+/- mice and associates with mammary tumor susceptibility of the BALB/c strain. Cancer Res. 2004 Aug 01; 64(15):5140-7.
    View in: PubMed
    Score: 0.008
  31. High susceptibility of nullizygous p53 knockout mice to colorectal tumor induction by 1,2-dimethylhydrazine. J Cancer Res Clin Oncol. 2003 Jun; 129(6):335-40.
    View in: PubMed
    Score: 0.008
  32. Elevated susceptibility of the p53 knockout mouse esophagus to methyl-N-amylnitrosamine carcinogenesis. Carcinogenesis. 2002 Sep; 23(9):1541-7.
    View in: PubMed
    Score: 0.007
  33. Visual genotyping of a coat color tagged p53 mutant mouse line. Cancer Biol Ther. 2002 Jul-Aug; 1(4):433-5.
    View in: PubMed
    Score: 0.007
  34. p53 knockout mice (-/-) are more susceptible than (+/-) or (+/+) mice to N-methyl-N-nitrosourea stomach carcinogenesis. Carcinogenesis. 2000 Oct; 21(10):1891-7.
    View in: PubMed
    Score: 0.006
  35. Cooperation between Ha-ras and fos or transforming growth factor alpha overcomes a paradoxic tumor-inhibitory effect of p53 loss in transgenic mouse epidermis. Mol Carcinog. 2000 Oct; 29(2):67-75.
    View in: PubMed
    Score: 0.006
  36. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 2000 Jun 15; 14(12):1448-59.
    View in: PubMed
    Score: 0.006
  37. Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression. Oncogene. 2000 Mar 23; 19(13):1635-46.
    View in: PubMed
    Score: 0.006
  38. Decreased immunoglobulin deposition in tumors and increased immature B cells in p53-null mice. Cell Growth Differ. 1997 Feb; 8(2):121-31.
    View in: PubMed
    Score: 0.005
  39. The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2. Proc Natl Acad Sci U S A. 1996 Nov 26; 93(24):14106-11.
    View in: PubMed
    Score: 0.005
  40. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha. Cancer Res. 1996 Oct 01; 56(19):4413-23.
    View in: PubMed
    Score: 0.005
  41. Androgen suppressed apoptosis is modified in p53 deficient mice. Oncogene. 1995 Apr 06; 10(7):1269-74.
    View in: PubMed
    Score: 0.004
  42. Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene. 1994 Nov; 9(11):3107-12.
    View in: PubMed
    Score: 0.004
  43. Infrequent p53 mutations in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in BALB/c and p53 hemizygous mice. Mol Carcinog. 1994 Mar; 9(3):175-83.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.